Robert F. Kennedy Jr.’s chances of becoming HHS chief likely hinge on one of his more controversial stances: that vaccines ...
Metsera and Maze Therapeutics priced their Nasdaq IPOs, raising $275M and $140M respectively. Both companies backed by ARCH ...
NHS England & Vertex reach deal for sickle cell gene therapy Casgevy, making it available at an undisclosed reduced price ...
AstraZeneca has canceled its plans to expand its vaccine manufacturing site in Speke, UK, after the new UK government trimmed ...
South Korean biopharma contract manufacturer Celltrion is considering acquiring US manufacturing sites to mitigate President ...
Genentech sues federal government over 340B discounts to STD clinics, joining Amgen, Eli Lilly and UCB in challenging program eligibility.
Daiichi Sankyo promoted Hiroyuki Okuzawa to CEO, and he will take over from Sunao Manabe on April 1. Okuzawa is currently Daiichi’s chief operating officer.
Merck announced Thursday that it prematurely stopped a Phase 3 study of Winrevair, a drug approved last year for a rare form ...
Hims & Hers releases Super Bowl ad criticizing pharmaceutical industry and weight loss market, promoting their compounded GLP ...
German CDMO Rentschler Biopharma is closing down its cell and gene therapy operations and shutting a facility in the UK, ...
Takeda CEO Christophe Weber will step down next June after more than 10 years leading the Japanese drugmaker. Julie ...
Rinvoq to $31B amid Humira decline. Skyrizi hit $11.7B and Rinvoq $5.97B in 2024, while Humira fell to $9B from $14.4B in 2023.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback